drugset / Trial / NCT00697801
Study of MAP0010 in Asthmatic Children and Adolescents
Phase 2
Completed
208 enrolled
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
Timeline
- Start
- 2006-07
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | — | Inhaled |